MetaCap

Cel-Sci (CVM) vs Pelthos Therapeutics (PTHS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pelthos Therapeutics (PTHS) has outperformed Cel-Sci (CVM) over the past year, losing 74.9% versus a loss of 80.7%. Pelthos Therapeutics is the larger company by market cap ($25.1 million vs $21.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CVM-80.67%PTHS-74.88%
+28%-31%-90%
Nov 21, 20251 yearNov 20, 2026
CVM-98.28%PTHS-86.71%
+5%-49%-103%
Feb 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CVM versus PTHS key metrics
MetricCVMPTHS
Share price$1.21$6.38
Market cap$21.28M$25.08M
1-day change-17.69%-8.73%
YTD return-77.00%-79.42%
1-year return-80.67%-74.88%
5-year return-99.61%—
EPS (TTM)$-1.69$-23.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$16.80M
Net income (latest FY)$-25.41M$-43.32M
Gross margin—76.25%
Operating margin—-193.09%
Net margin—-257.93%
52-week high$7.80$31.62
52-week low$0.89$6.02
Distance from 52-week high-84.49%-79.82%
Analyst consensusnonestrong_buy
Avg. price target upside+933.06%+732.92%
Average volume231.46K54.38K
Shares outstanding17.59M3.93M
Employees—92
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cel-Sci

CVM stock →

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About Pelthos Therapeutics

PTHS stock →

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees

CVM vs PTHS FAQ

Which is bigger, Cel-Sci or Pelthos Therapeutics?

Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $25.08M compared with $21.28M for Cel-Sci (CVM).

Which stock has performed better over the past year, CVM or PTHS?

PTHS returned -74.88% over the past 12 months, compared with -80.67% for CVM (price return, excluding dividends). Past performance does not predict future results.

Are Cel-Sci and Pelthos Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons